NEW YORK, March 19, 2019 /PRNewswire/ -- Hoth Therapeutics,
Inc. (NASDAQ: HOTH), a development-stage biopharmaceutical
company focused on unique targeted therapeutics for patients
suffering from indications such as atopic dermatitis–also known as
eczema–as well as dermatological and chronic wound disorders,
today announced the addition of Dr. Stefanie Johns to
the Company's Scientific Advisory Board. The Scientific
Advisory Board was formed to assist the Company in developing the
BioLexa Platform and other therapeutics. The BioLexa Platform
is a proprietary, patented, drug compound platform developed at
the University of Cincinnati.
Dr. Stefanie Johns, Ph.D. is the
Associate Director, Regulatory Affairs at Enable Injections, LLC, a
company specializing in the development and manufacture of advanced
wearable infusion devices for use in combination products.
Dr. Johns completed her graduate work in protein biochemistry at
the University of Cincinnati College of
Medicine under the direction of Dr. Andrew
Herr, Ph.D., whom also contributed to the development of the
BioLexa Platform technology. After graduate school, Dr. Johns
joined Xavier Health Initiatives as the Program Manager where she
assisted with collaborative initiatives with both pharmaceutical
and medical device industry leaders, division leaders from the
United States Food and Drug Administration, and members of the
Senate Health, Education Labor & Pensions committee. She
continued her career in regulatory affairs providing strategic
regulatory guidance for medical device, drug, and drug-device
combination product development programs at Meridian Bioscience and
Camargo Pharmaceutical Services. While at Camargo, Dr. Johns led
the planning and implementation of the early regulatory strategy
for the BioLexa program.
Dr. Johns commented, "I am excited to continue working with Hoth
Therapeutics on the development of the BioLexa Platform as a novel
therapeutic for treatment of dermatological and chronic wound
disorders. Chronic dermatological diseases, including atopic
dermatitis, cause significant burden on patients and their families
and it is important to have novel treatment options available,
particularly for patients whose disease is not currently controlled
by existing therapies."
About Hoth Therapeutics, Inc.
Hoth Therapeutics,
Inc., a Nevada corporation, is a development stage
biopharmaceutical company focused on unique targeted therapeutics
for patients suffering from indications such as atopic dermatitis,
also known as eczema. Hoth has exclusive worldwide rights to the
BioLexa Platform.
Forward Looking Statements
This press release includes
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements in this press release include, but are not limited to,
statements that relate to the advancement and development of the
BioLexa Platform, the commencement of clinical trials, the
availability of data from clinical trials and other information
that is not historical information. When used herein, words such as
"anticipate", "being", "will", "plan", "may", "continue", and
similar expressions are intended to identify forward-looking
statements. In addition, any statements or information that refer
to expectations, beliefs, plans, projections, objectives,
performance or other characterizations of future events or
circumstances, including any underlying assumptions, are
forward-looking. All forward-looking statements are based upon
Hoth's current expectations and various assumptions. Hoth believes
there is a reasonable basis for its expectations and beliefs, but
they are inherently uncertain.
Hoth may not realize its expectations, and its beliefs may not
prove correct. Actual results could differ materially from those
described or implied by such forward-looking statements as a result
of various important factors, including, without limitation, market
conditions and the factors described under the caption "Risk
Factors" in Hoth's Prospectus, dated February 14, 2019, and Hoth's other filings made
with the Securities and Exchange Commission. Consequently,
forward-looking statements should be regarded solely as Hoth's
current plans, estimates and beliefs. Investors should not place
undue reliance on forward-looking statements. Hoth cannot guarantee
future results, events, levels of activity, performance or
achievements. Hoth does not undertake and specifically declines any
obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by law.
Contact
Investor Relations Contact:
Phone: (646) 756-2997
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-inc-announces-the-addition-of-dr-stefanie-johns-phd-to-the-companys-scientific-advisory-board-300814376.html
SOURCE Hoth Therapeutics, Inc.